WO1999060989A2 - Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination - Google Patents

Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination Download PDF

Info

Publication number
WO1999060989A2
WO1999060989A2 PCT/EP1999/003362 EP9903362W WO9960989A2 WO 1999060989 A2 WO1999060989 A2 WO 1999060989A2 EP 9903362 W EP9903362 W EP 9903362W WO 9960989 A2 WO9960989 A2 WO 9960989A2
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
hair
glycoprotein
active ingredient
ingredient combination
Prior art date
Application number
PCT/EP1999/003362
Other languages
German (de)
French (fr)
Other versions
WO1999060989A3 (en
Inventor
Detlef Hollenberg
Ullrich Bernecker
Original Assignee
Henkel Kommanditgesellschaft Auf Aktien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Kommanditgesellschaft Auf Aktien filed Critical Henkel Kommanditgesellschaft Auf Aktien
Priority to EP99953283A priority Critical patent/EP1079795A2/en
Priority to AU42625/99A priority patent/AU4262599A/en
Priority to CA002333544A priority patent/CA2333544A1/en
Priority to JP2000550450A priority patent/JP2002516263A/en
Publication of WO1999060989A2 publication Critical patent/WO1999060989A2/en
Publication of WO1999060989A3 publication Critical patent/WO1999060989A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988—Honey; Royal jelly, Propolis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures

Definitions

  • the invention relates to preparations with a special combination of active ingredients consisting of biotin and at least one glycoprotein for the treatment of human skin and hair and the use of this combination of active ingredients.
  • an active ingredient combination consisting of biotin and at least one glycoprotein increases protein production in human cells when administered topically.
  • an active ingredient combination consisting of biotin and at least one glycoprotein increases protein production in human cells when administered topically.
  • a first subject of the invention is therefore preparations for the treatment of human skin and hair, characterized in that they contain an active ingredient combination consisting of biotin and at least one glycoprotein.
  • the first component of the active ingredient combination according to the invention is biotin.
  • Biotin means (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4 - ⁇ - t] -imidazole-4-valeric acid.
  • the compound is also called vitamin H or vitamin B 7 .
  • the active ingredient combination according to the invention contains at least one glycoprotein.
  • Glycoproteins are compounds that contain carbohydrates and protein in the same molecule.
  • glycoproteins of plant origin are preferred according to the invention, the glycoprotein in particular originating from a primary plant cell wall.
  • glycoproteins from soybeans, rice, oats, wheat, potatoes, peaches, almonds, mushrooms and peas have proven to be particularly suitable according to the invention.
  • Glycoproteins from soybeans are particularly preferred according to the invention. Hydroxyproline-rich glycoproteins or extensins, arabinogalactan proteins and proline-rich proteins can be obtained from the primary cell wall of soybeans be won. About 20-30% by weight of the dry mass of the primary soybean cell wall consists of these three components.
  • glycoproteins used according to the invention preferably contain arabinose, galactose, mannose, glucose and fucose as the carbohydrate component.
  • Arabinose and galactose are preferred carbohydrates.
  • An inventively particularly suitable glycoprotein is obtainable under the name Phytodermin ® commercial product.
  • the preparations according to the invention preferably contain biotin in amounts of 0.000001-0.5% by weight, based on the entire preparation. Amounts of 0.000005-0.05% by weight, in particular 0.00001-0.01% by weight, are particularly preferred.
  • glycoproteins are contained in the preparations according to the invention preferably in amounts of 0.0001-5% by weight, in particular 0.001-1% by weight, also based on the entire preparation.
  • the active ingredient combination according to the invention can in principle be incorporated into all customary hair and skin treatment compositions, provided that this is not precluded by known instabilities.
  • the biotin is unstable in combination with strong oxidizing agents.
  • Preparations with such incompatibilities should not be excluded in principle in the context of the present invention. Rather, according to the invention, it may well be possible in this case to pack one of the incompatible components separately and to add them to the preparation only immediately before use.
  • the preparations according to the invention also contain at least one penetration aid.
  • Penetration aids which can be used according to the invention are, for example, polyethylene glycols with molar masses of about 200 to 45,000, in particular about 400, Glycols, urea and glucose as well as glycerin, propylene glycol monoethyl ether, carbonates, hydrogen carbonates, guanidines, as well as primary, secondary and tertiary phosphates.
  • Preferred penetration aids are the polyethylene glycols, propylene glycols, butylene glycols, urea and glucose.
  • the preparations according to the invention preferably contain the penetration aids in amounts of 0.1-15% by weight, based on the entire preparation. Quantities of 0.1-10% by weight are preferred for the skin application area and amounts of 0.1-15% by weight are preferred for the hair application area. In both cases, amounts of approximately 0.1-5% by weight are particularly preferred.
  • the agents according to the invention contain a protein hydrolyzate.
  • this includes both the protein hydrolyzates themselves and their condensation products with fatty acids and quaternized protein hydrolyzates.
  • Preferred protein hydrolyzates are elastin, collagen, keratin, milk protein, soy protein, almond protein, pea protein, rice protein and wheat protein hydrolyzates. Vegetable protein hydrolyzates are particularly preferred.
  • those protein hydrolyzates which have a high proportion of the amino acids hydroxyproline and proline are particularly suitable according to the invention.
  • the protein hydrolyzates are preferably present in the agents according to the invention in amounts of 0.05-5% by weight, based on the total agent.
  • the preparations according to the invention contain a further vitamin component selected from panthenol, tocopherol and vitamin A and their precursors and derivatives.
  • panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and cationically derivatized panthenols.
  • Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate and the cationic panthenol derivatives disclosed in WO 92/13829.
  • Panthenol itself is preferred within this group.
  • Panthenol and its derivatives are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5% by weight are particularly preferred.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, derivatives are preferably contained in the preparations according to the invention in amounts of 0.05-1% by weight, based on the preparation as a whole .
  • vitamin A acid and its esters vitamin A aldehyde and vitamin A alcohol and its esters such as palmitate and acetate are suitable as vitamin A components.
  • the preparations according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the entire preparation.
  • the preparations according to the invention contain a plant extract.
  • extracts are usually produced by extracting the entire plant. In individual cases, however, it may also be preferred to produce the extracts exclusively from flowers and / or leaves of the plant.
  • the extracts from almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi, melon and green tea are particularly suitable for the use according to the invention.
  • Water, alcohols, water-alcohol mixtures and CO 2 can be used as extractants for the production of the plant extracts mentioned.
  • the alcohols lower alcohols such as ethanol and isopropanol, but in particular polyhydric alcohols such as ethylene glycol and propylene glycol, are preferred, both as the sole extracting agent and in a mixture with water.
  • Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
  • the plant extracts can be used both in pure and in diluted form. If they are used in dilute form, they usually contain about 2 to 80% by weight of active substance and, as a solvent, the extractant or mixture of extractants used in their extraction.
  • mixtures of several, in particular two, different plant extracts in the agents according to the invention may be preferred.
  • Honey extracts are obtained in an analogous manner to the plant extracts and usually contain 1 to 10% by weight, in particular 3 to 5% by weight, of active substance.
  • Water / propylene glycol mixtures can also be preferred extraction agents here.
  • Plant extracts are used in agents according to the invention preferably in amounts of 0.1-20% by weight, in particular in amounts of 0.2-8% by weight. Amounts of 0.5-5% by weight can be very particularly preferred. These quantities are on the one hand based on the total agent according to the invention, on the other hand on the plant extract in the form in which it is added to the agent. As already stated above, this can be both a pure plant extract and a solution with usually 2-80% by weight of active substance.
  • the preparations according to the invention preferably also contain a film former.
  • Ionic and in particular nonionic polymers are particularly suitable as film formers.
  • Preferred nonionic polymers are polyvinyl pyrrolidone and vinyl pyrrolidone / vinyl acetate copolymers (for example the products Luviskol ® K 30, K90, NA 64 and VA 37), and polysiloxanes (such as the commercial products Dow Corning 345, 190, 193, 200, 245, 246 , 1401 and 1403).
  • preferred cationic polymers are quaternized cellulose ethers such as for example the commercial product Polymer JR ® 400, polysiloxanes with quaternary groups such as Dow Corning DC ® 929, dimethyldiallylammonium chloride polymers such as Merquat ® 100, acrylamide-dimethyl diallyl ammonium chloride copolymers, such as Merquat ® 550, quaternized with diethyl sulfate dimethylaminoethyl Vinylpyrrolidone copolymers such as Gafquat ® 734 and 755, vinylpyrrolidone-imidazolinium methochloride copolymers such as the commercial products of the Luviquat ® series and quaternized polyvinyl alcohol.
  • quaternized cellulose ethers such as for example the commercial product Polymer JR ® 400, polysiloxanes with quaternary groups such as Dow Corning DC ® 929, dimethyldiallylammonium chlor
  • Suitable zwitterionic and amphoteric polymers are, for example, acrylamido- propyl-trimethylammonium chloride / acrylate copolymers, octylacrylamide / acrylate Methylmeth- / tert.Butylaminoethylmethacrylat / 2-hydroxypropyl methacrylate copolymers such as the product Amphomer ® and dimethyl diallyl ammonium chloride-acrylic acid copolymers such as the product Merquat ® 280th
  • Anionic polymers preferred according to the invention are polyacrylic acids and crosslinked polyacrylic acids such as, for example, the commercial products of the Carbopol ® series, in particular Carbopol ® ETD 2020, vinyl acetate / crotonic acid copolymers and terpolymers such as the products of the Luviset ® series, vinylpyrrolidone / vinyl acrylate copolymers, Vinyl acetate / but
  • the preparations according to the invention can be formulated on an aqueous, aqueous-alcoholic or alcoholic basis.
  • Lower alcohols such as ethanol and isopropanol are particularly suitable as alcohols.
  • Aqueous-alcoholic bases can preferably contain water and alcohol in a ratio of 1: 5 to 5: 1.
  • the active ingredient combination according to the invention can be applied to the hair both in the form of a separate formulation or as an additional component in other agents.
  • the preparations according to the invention are formulated as a hair tonic, hair conditioner or as a hair treatment.
  • Hair tonics usually remain on the hair until the next hair treatment, e.g. daily shampooing.
  • Hair rinses are generally formulated in such a way that the active ingredients are rinsed out with water or an at least predominantly water-containing agent after the desired exposure time.
  • the contact time with the hair is usually short.
  • Hair treatments contain the active ingredient combination in a higher concentration than hair rinses and are intended for intensive treatment of the hair and possibly the scalp.
  • the exposure time can be short, for example in the order of the exposure time of hair rinses, but it can also be up to 20 minutes depending on the degree of damage to the hair.
  • the hair treatments according to the invention can also be rinsed out with water or an at least predominantly water-containing agent; but you can also on the Hair left.
  • these agents can be formulated as foam aerosols.
  • the agents can contain propellant gases.
  • the formulation as a pump spray with air as the blowing agent is preferred.
  • the agents according to the invention can include, for example, cleaning agents such as shampoos, setting agents such as hair setting agents, hair sprays and blow dryer waves, permanent shaping agents such as permanent wave and fixing agents, color-changing agents such as bleaching agents, oxidation dyes and tinting agents based on direct dyes, hair lotions and Trade tip fluids.
  • cleaning agents such as shampoos
  • setting agents such as hair setting agents, hair sprays and blow dryer waves
  • permanent shaping agents such as permanent wave and fixing agents
  • color-changing agents such as bleaching agents, oxidation dyes and tinting agents based on direct dyes, hair lotions and Trade tip fluids.
  • the preparations according to the invention can be packaged, for example, as skin care agents and skin cleansers. Particularly in the case of skin treatment agents, those preparations are preferred according to the invention which remain on the body, here the skin, after application.
  • the preparations can be formulated as solutions, oil-in-water emulsions, water-in-oil emulsions, nanoemulsions, microemulsions, in particular those of the PIT type, gels, creams, aerosols or lotions.
  • the preparations can also be in encapsulated form, for example in gelatin or polyvinyl alcohol, as well as in the form of liposomes, e.g. with lecithin.
  • the preparations according to the invention may contain the further constituents customary in these agents.
  • Further common constituents of the preparations according to the invention can thus be: anionic surfactants such as, in particular, alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids with 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, and also sulfosuccinic acid and dialkyl esters with 8 to 18 carbon atoms in the alkyl group and sulfosuccinic acid mono-alkyl polyoxyethyl ester 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups.
  • anionic surfactants such as, in particular, alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids with 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in
  • nonionic surfactants such as, in particular, adducts of 2 to 30 mol of ethylene oxide and / or 0 to 5 mol of propylene oxide with linear fatty alcohols with 8 to 22 C atoms, with fatty acids with 12 to 22 C atoms, with alkylphenols with 8 to 15 C atoms in the alkyl group and corresponding fatty acid amides and fatty amines, -C 22 -C fatty acid mono- and diesters of adducts of 1 to 30 mol ethylene oxide with glycerol, C 8 -C alkyl mono- and oligoglycosides and their ethoxylated analogs, fatty acid N-alkylglucamides , Addition products of 5 to 60 moles of ethylene oxide with castor oil and hardened castor oil, polyol fatty acid esters, sugar esters, sorbitan esters and polysorbates.
  • nonionic surfactants contain polyglycol ether chains, they can have a conventional or narrow homolog distribution.
  • zwitterionic surfactants in particular the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyl dimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyl dimethylammonium glycinate, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyl dimethylammonium glycinate,
  • ampholytic surfactants such as N-alkylglycine, N-alkylpropionic acid, N-alkylamino-butyric acid, N-alkyliminodipropionic acid, N-hydroxyethyl-N-alkylamido propylglycine, N-alkyltaurine, N-alkyl sarcosine, 2-alkylaminopropionic acid and alkylaminoacetic acid each with about 8 to 18 C atoms in the alkyl group, cationic surfactants of the quaternary ammonium compound type, preferably ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, for.
  • ammonium halides in particular chlorides and bromides
  • 2-Dihydroxypropyldialkylaminen on the one hand and fatty acids such as caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, isostearic acid, stearic acid, oleic acid, elaidic acid, arachidic acid, behenic acid and erucic acid or their technical mixtures, as they occur, for example, in the pressure and oil splitting of natural fats such as those available under the trademark Dehyquart® ® and Armocare® ® available products as well as the type of Alkylamidoamine as Stearamidopropyldimethy obtainable under the name Tegoamid ® S 18.
  • fatty acids such as caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, isostearic acid, stearic acid, oleic acid, elaidic acid, arachidic acid, behenic acid and erucic acid or their
  • dialkyl ethers with a total of between 12 to 36 carbon atoms, in particular 12 to 24 carbon atoms, for example di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di- n-undecyl ether and di-n-dodecyl ether, n-hexyl-n-octyl ether, n-octyl-n-decyl ether, n-decyl-n-undecyl ether, n-undecyl-n-dodecyl ether and n-hexyl-n-undecyl ether as well Di-tert-butyl ether, di-isopentyl ether, di-3-ethyl decyl ether, tert-butyl-n-octyl ether
  • Thickening agents such as agar agar, guar gum, alginates, xanthan gum, gelatin, pectins, hydroxyethyl cellulose and polyacrylamides and their copolymers, structurants such as maleic acid,
  • Mono-, di- and oligosaccharides such as glucose, galactose, fructose, fructose and lactose, ceramides, vegetable oils such as jojoba oil, sunflower oil, orange oil, almond oil, wheat germ oil and peach seed oil as well as paraffin oils, saturated and unsaturated, linear and branched fatty alcohols with 8 to 22 carbon atoms and their mixtures, which are reduced by naturally occurring Triglycerides such as beef tallow, palm oil, peanut oil, rape oil, cottonseed oil, soybean oil,
  • Soy lecithin, egg lecithin and cephaline Soy lecithin, egg lecithin and cephaline
  • Solubilizers such as ethanol, isopropanol, ethylene glycol, propylene glycol,
  • Anti-dandruff agents such as piroctone olamine, zinc omadine and climbazole, other substances for adjusting the pH value
  • Active ingredients such as allantoin, pyrrolidone carboxylic acids and bisabolol,
  • Consistency enhancers such as sugar esters, polyol esters or polyol alkyl ethers,
  • Fats and waxes such as walrus, beeswax, montan wax and paraffins,
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • Pearlescent agents such as ethylene glycol mono- and distearate and PEG-3 distearate,
  • Complexing agents such as EDTA, NTA, ß-alaninediacetic acid and phosphonic acids, direct dyes so-called coupler and developer components as oxidation dye precursors,
  • Reducing agents such as Thioglycolic acid and its derivatives, thiolactic acid,
  • Oxidizing agents such as hydrogen peroxide, potassium bromate and sodium bromate
  • Blowing agents such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 , N 2 and air as well
  • the pH of the preparations according to the invention can in principle be between 4.5 and 7, the instabilities known to the person skilled in the art, for example the base body panthenol in an alkaline environment, being taken into account.
  • the pH of the agents according to the invention is preferably between 6 and 6.5. Virtually any acid that can be used for cosmetic purposes can be used to adjust this pH.
  • Food acids are usually used.
  • Edible acids are understood to mean those acids that are ingested as part of normal food intake and have positive effects on the human organism. Examples of edible acids are acetic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid and gluconic acid. In the context of the invention, the use of lactic acid and citric acid is particularly preferred.
  • Further objects of the invention are the use of a combination of active ingredients, consisting of biotin and at least one glycoprotein, for the treatment of human skin and hair, and the use of this combination of active ingredients for increasing protein production in human cells.
  • Mixture VI is a physiological saline solution diluted by a factor of 10. Unless otherwise noted, all quantities are parts by weight.
  • Phenoxyethanol (and) methylparaben (and) propylparaben) (HENKEL)
  • Polyacrylic acid copolymer (INCI name: Acrylates / C 10-30 alkyl acrylates

Abstract

The invention relates to preparations which contain an active ingredient combination made up of biotin and of at least one glycoprotein. Said preparations increase cell vitality. By applying corresponding agents on skin or hair, corresponding increases in vitality are obtained which, for example, lead to an improved elasticity of the skin.

Description

„Zubereitung zur Behandlung der menschlichen Haut und der menschlichen Haare mit einer speziellen Wirkstoffkombination sowie Verwendung dieser“Preparation for the treatment of human skin and hair with a special combination of active ingredients and the use of these
Wirkstoffkombination"Drug combination "
Die Erfindung betrifft Zubereitungen mit einer speziellen Wirkstoffkombination aus Biotin sowie mindestens einem Glykoprotein zur Behandlung der menschlichen Haut und der menschlichen Haare sowie die Verwendung dieser Wirkstoffkombination.The invention relates to preparations with a special combination of active ingredients consisting of biotin and at least one glycoprotein for the treatment of human skin and hair and the use of this combination of active ingredients.
Menschliche Haut und menschliches Haar werden in vielfältiger Weise mit kosmetischen Zubereitungen behandelt. Dazu gehören seit alters her insbesondere die Reinigung und die Pflege von Haut und Haaren. In jüngerer Zeit finden aber solche Produkte ein immer größeres Interesse, die neben der üblichen Reinigung oder Pflege die Konservierung oder Wiederherstellung eines Zustandes bewirken sollen, der einem bestimmten Schönheitsideal entspricht. Dazu zählen neben der Abdeckung von grauen Haaren insbesondere der Erhalt oder Wiederaufbau vitalen Haares und eines vollen Haarschopfes sowie ein Entgegenwirken der Faltenbildung der Haut. Es besteht somit ein steigender Bedarf an neuen Wirkstoffen bzw. Wirkstoffkombinationen mit entsprechenden positiven Auswirkungen auf Haut und Haare. Diese Wirkstoffe und Wirkstoffkombinationen können in Form spezieller Formulierungen appliziert werden. Vorteilhafterweise sollten sie aber auch in übliche Haut- und Haarbehandlungsmittel eingearbeitet werden können und dann bei deren Anwendung die gewünschte Zusatzwirkung entfalten.Human skin and hair are treated in a variety of ways with cosmetic preparations. Since time immemorial, this has included cleaning and caring for the skin and hair. Recently, however, there has been increasing interest in products which, in addition to the usual cleaning or care, are intended to preserve or restore a condition which corresponds to a certain ideal of beauty. In addition to covering gray hair, this includes in particular maintaining or restoring vital hair and a full head of hair as well as counteracting the wrinkling of the skin. There is therefore an increasing need for new active substances or combinations of active substances with corresponding positive effects on skin and hair. These active ingredients and combinations of active ingredients can be applied in the form of special formulations. However, they should advantageously also be able to be incorporated into customary skin and hair treatment agents and then develop the desired additional action when used.
Es wurde nun überraschenderweise gefunden, daß eine Wirkstoffkombination, bestehend aus Biotin und mindestens einem Glykoprotein, bei topischer Applikation die Proteinproduktion in menschlichen Zellen steigert. Als Folge einer entsprechenden Applikation wird nicht nur den oben genannten ungewünschten Entwicklungen entgegengewirkt, sondern es tritt auch, einhergehend mit der Steigerung der Vitalität der Zellen, eine signifikante Steigerung der Vitalität von Haut und Haaren auf, die sich beispielsweise in einer verbesserten Hautelastizität zeigt.It has now surprisingly been found that an active ingredient combination consisting of biotin and at least one glycoprotein increases protein production in human cells when administered topically. As a result of a corresponding application, not only the undesired developments mentioned above are counteracted, but it also occurs, accompanied by an increase in the vitality of the Cells, a significant increase in the vitality of the skin and hair, which is shown, for example, in an improved skin elasticity.
Ein erster Gegenstand der Erfindung sind daher Zubereitungen zur Behandlung der menschlichen Haut und der menschlichen Haare, dadurch gekennzeichnet, daß sie eine Wirkstoffkombination, bestehend aus Biotin und mindestens einem Glykoprotein, enthalten.A first subject of the invention is therefore preparations for the treatment of human skin and hair, characterized in that they contain an active ingredient combination consisting of biotin and at least one glycoprotein.
Sowohl Biotin (s. z. B. Fey, Otto, Wörterbuch der Kosmetik, 4. Auflage, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1997, Seite 39) als auch Glykoproteine (s. z. B. Produktspezifikation 12/94 zu „Phytodermin" von der Firma Chemisches Laboratorium Dr. Kurt Richter GmbH, Berlin) sind als Wirkstoffe für Kosmetika bekannt. Diese Druckschriften geben jedoch keinen Hinweis auf die erfindungsgemäße Kombination oder deren Einfluß auf die Proteinproduktion in menschlichen Zellen und die dadurch bewirkten positiven Effekte auf menschliche Haut und Haare.Both biotin (see, for example, Fey, Otto, Dictionary of Cosmetics, 4th edition, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1997, page 39) and glycoproteins (see, for example, product specification 12/94 for "Phytodermin" from the company Chemisches Laboratorium Dr. Kurt Richter GmbH, Berlin) are known as active ingredients for cosmetics, but these publications give no indication of the combination according to the invention or its influence on protein production in human cells and the positive effects on human skin and hair caused thereby.
Die erste Komponente der erfindungsgemäßen Wirkstoffkombination ist Biotin. Unter Biotin versteht man (3aS,4S, 6aR)-2-Oxohexahydrothienol[3,4-<-t]-imidazol-4- valeriansäure. Die Verbindung wird auch als Vitamin H bzw. Vitamin B7 bezeichnet.The first component of the active ingredient combination according to the invention is biotin. Biotin means (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4 - <- t] -imidazole-4-valeric acid. The compound is also called vitamin H or vitamin B 7 .
Weiterhin enthält die erfindungsgemäße Wirkstoffkombination mindestens ein Glykoprotein. Als Glykoproteine werden Verbindungen bezeichnet, die im selben Molekül Kohlenhydrate und Protein enthalten.Furthermore, the active ingredient combination according to the invention contains at least one glycoprotein. Glycoproteins are compounds that contain carbohydrates and protein in the same molecule.
Erfindungsgemäß bevorzugt sind Glykoproteine pflanzlicher Herkunft, wobei das Glykoprotein insbesondere aus einer primären Pflanzenzellwand stammt.Glycoproteins of plant origin are preferred according to the invention, the glycoprotein in particular originating from a primary plant cell wall.
Als erfindungsgemäß besonders geeignet haben sich die Glykoproteine aus Sojabohnen, Reis, Hafer, Weizen, Kartoffeln, Pfirsichen, Mandeln, Pilzen und Erbsen erwiesen. Glykoproteine aus Sojabohnen sind erfindungsgemäß besonders bevorzugt. Aus der primären Zellwand von Sojabohnen können insbesondere hydroxyprolinreiche Glykoproteine oder Extensine, Arabinogalactan-Proteine sowie prolinreiche Proteine gewonnen werden. Etwa 20-30 Gew.-% der Trockenmasse der primären Zellwand der Sojabohnen bestehen aus diesen drei Komponenten.The glycoproteins from soybeans, rice, oats, wheat, potatoes, peaches, almonds, mushrooms and peas have proven to be particularly suitable according to the invention. Glycoproteins from soybeans are particularly preferred according to the invention. Hydroxyproline-rich glycoproteins or extensins, arabinogalactan proteins and proline-rich proteins can be obtained from the primary cell wall of soybeans be won. About 20-30% by weight of the dry mass of the primary soybean cell wall consists of these three components.
Als Kohlenhydratanteil enthalten die erfindungsgemäß verwendeten Glykoproteine bevorzugt Arabinose, Galactose, Mannose, Glucose und Fucose. Arabinose und Galactose sind bevorzugte Kohlenhydrate.The glycoproteins used according to the invention preferably contain arabinose, galactose, mannose, glucose and fucose as the carbohydrate component. Arabinose and galactose are preferred carbohydrates.
Ein erfindungsgemäß besonders geeignetes Glykoprotein ist das unter der Bezeichnung Phytodermin® im Handel erhältliche Produkt.An inventively particularly suitable glycoprotein is obtainable under the name Phytodermin ® commercial product.
Die erfindungsgemäßen Zubereitungen enthalten Biotin bevorzugt in Mengen von 0,000001-0,5 Gew.-%, bezogen auf die gesamte Zubereitung. Mengen von 0,000005-0,05 Gew.-%, insbesondere 0,00001-0,01 Gew.-%, sind besonders bevorzugt.The preparations according to the invention preferably contain biotin in amounts of 0.000001-0.5% by weight, based on the entire preparation. Amounts of 0.000005-0.05% by weight, in particular 0.00001-0.01% by weight, are particularly preferred.
Die Glykoproteine sind in den erfindungsgemäßen Zubereitungen bevorzugt in Mengen von 0,0001-5 Gew.-%, insbesondere 0,001-1 Gew.-%, ebenfalls bezogen auf die gesamte Zubereitung, enthalten.The glycoproteins are contained in the preparations according to the invention preferably in amounts of 0.0001-5% by weight, in particular 0.001-1% by weight, also based on the entire preparation.
Die erfindungsgemäße Wirkstoffkombination kann prinzipiell in alle üblichen Haar- und Hautbehandlungsmittel eingearbeitet werden, soweit nicht bekannte Instabilitäten dies ausschließen. So ist das Biotin beispielsweise in Kombination mit starken Oxidationsmitteln instabil. Zubereitungen mit solchen Inkompatibilitäten sollen aber im Rahmen der vorliegenden Erfindung nicht prinzipiell ausgeschlossen werden. Vielmehr kann es erfindungsgemäß durchaus möglich sein, in diesem Fall eine der inkompatiblen Komponenten getrennt abzupacken und der Zubereitung erst unmittelbar vor der Anwendung zuzugeben.The active ingredient combination according to the invention can in principle be incorporated into all customary hair and skin treatment compositions, provided that this is not precluded by known instabilities. For example, the biotin is unstable in combination with strong oxidizing agents. Preparations with such incompatibilities should not be excluded in principle in the context of the present invention. Rather, according to the invention, it may well be possible in this case to pack one of the incompatible components separately and to add them to the preparation only immediately before use.
Gemäß einer ersten bevorzugten Ausführungsform enthalten die erfindungsgemäßen Zubereitungen noch mindestens ein Penetrationshilfsmittel.According to a first preferred embodiment, the preparations according to the invention also contain at least one penetration aid.
Erfindungsgemäß verwendbare Penetrationshilfsmittel sind beispielsweise Polyethylenglykole mit Molmassen von etwa 200 bis 45 000, insbesondere etwa 400, Glykole, Harnstoff und Glucose sowie Glycerin, Propylenglykolmonoethylether, Carbonate, Hydrogencarbonate, Guanidine, sowie primäre, sekundäre und tertiäre Phosphate. Bevorzugte Penetrationshilfsmittel sind die Polyethylenglykole, Propylenglykole, Butylenglykole, Harnstoff und Glucose.Penetration aids which can be used according to the invention are, for example, polyethylene glycols with molar masses of about 200 to 45,000, in particular about 400, Glycols, urea and glucose as well as glycerin, propylene glycol monoethyl ether, carbonates, hydrogen carbonates, guanidines, as well as primary, secondary and tertiary phosphates. Preferred penetration aids are the polyethylene glycols, propylene glycols, butylene glycols, urea and glucose.
Die erfindungsgemäßen Zubereitungen enthalten die Penetrationshilfsmittel bevorzugt in Mengen von 0,1-15 Gew.-%, bezogen auf die gesamte Zubereitung. Für das Anwendungsgebiet Haut sind Mengen von 0,1-10 Gew.-%, für das Anwendungsgebiet Haar Mengen von 0,1-15 Gew.-% bevorzugt. Besonders bevorzugt sind in beiden Fällen Mengen von etwa 0,1-5 Gew. -%.The preparations according to the invention preferably contain the penetration aids in amounts of 0.1-15% by weight, based on the entire preparation. Quantities of 0.1-10% by weight are preferred for the skin application area and amounts of 0.1-15% by weight are preferred for the hair application area. In both cases, amounts of approximately 0.1-5% by weight are particularly preferred.
Gemäß einer zweiten Ausführungsform enthalten die erfindungsgemäßen Mittel ein Proteinhydrolysat. Darunter werden im Rahmen der Anmeldung sowohl die Proteinhydrolysate selbst als auch deren Kondensationsprodukte mit Fettsäuren sowie quaternisierte Proteinhydrolysate verstanden. Bevorzugte Proteinhydrolysate sind Elastin- , Kollagen-, Keratin-, Milcheiweiß-, Sojaprotein-, Mandelprotein-, Erbsenprotein, Reisprotein- und Weizenproteinhydrolysate. Pflanzliche Proteinhydrolysate sind besonders bevorzugt. Weiterhin sind solche Proteinhydrolysate, die einen hohen Anteil an den Aminosäuren Hydroxyprolin und Prolin aufweisen, erfindungsgemäß besonders geeignet. Die Proteinhydrolysate sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05 - 5 Gew.-%, bezogen auf das gesamte Mittel, enthalten.According to a second embodiment, the agents according to the invention contain a protein hydrolyzate. In the context of the application, this includes both the protein hydrolyzates themselves and their condensation products with fatty acids and quaternized protein hydrolyzates. Preferred protein hydrolyzates are elastin, collagen, keratin, milk protein, soy protein, almond protein, pea protein, rice protein and wheat protein hydrolyzates. Vegetable protein hydrolyzates are particularly preferred. Furthermore, those protein hydrolyzates which have a high proportion of the amino acids hydroxyproline and proline are particularly suitable according to the invention. The protein hydrolyzates are preferably present in the agents according to the invention in amounts of 0.05-5% by weight, based on the total agent.
Gemäß einer weiteren bevorzugten Ausfuhrungsform enthalten die erfindungsgemäßen Zubereitungen eine weitere Vitaminkomponente, ausgewählt aus Panthenol, Tocopherol und Vitamin A sowie deren Vorstufen und Derivate.According to a further preferred embodiment, the preparations according to the invention contain a further vitamin component selected from panthenol, tocopherol and vitamin A and their precursors and derivatives.
Erfindungsgemäß einsetzbare Derivate des Panthenols sind insbesondere die Ester und Ether des Panthenols sowie kationisch derivatisierte Panthenole. Einzelne Vertreter sind beispielsweise das Panthenoltriacetat, der Panthenolmonoethylether und dessen Monoacetat sowie die der WO 92/13829 offenbarten kationischen Panthenolderivate. Panthenol selbst ist innerhalb dieser Gruppe bevorzugt. Panthenol und seine Derivate sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05 - 10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1 - 5 Gew.-% sind besonders bevorzugt. Tocopherol und seine Derivate, worunter insbesondere die Ester wie das Acetat, das Nicotinat, das Phosphat und das Succinat fallen, Derivate sind in den erfindungsgemäßen Zubereitungen bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf die gesamte Zubereitung, enthalten.Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and cationically derivatized panthenols. Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate and the cationic panthenol derivatives disclosed in WO 92/13829. Panthenol itself is preferred within this group. Panthenol and its derivatives are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5% by weight are particularly preferred. Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, derivatives are preferably contained in the preparations according to the invention in amounts of 0.05-1% by weight, based on the preparation as a whole .
Als Vitamin A-Komponente kommen erfindungsgemäß beispielsweise Vitamin A-Säure und deren Ester, Vitamin A-Aldehyd und Vitamin A-Alkohol dessen Ester wie das Palmitat und das Acetat in Betracht. Die erfindungsgemäßen Zubereitungen enthalten die Vitamin A-Komponente bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf die gesamte Zubereitung.According to the invention, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as palmitate and acetate are suitable as vitamin A components. The preparations according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the entire preparation.
Gemäß einer weiteren bevorzugten Ausführungsform enthalten die erfindungsgemäßen Zubereitungen einen Pflanzenextrakt.According to a further preferred embodiment, the preparations according to the invention contain a plant extract.
Üblicherweise werden diese Extrakte durch Extraktion der gesamten Pflanze hergestellt. Es kann aber in einzelnen Fällen auch bevorzugt sein, die Extrakte ausschließlich aus Blüten und/oder Blättern der Pflanze herzustellen.These extracts are usually produced by extracting the entire plant. In individual cases, however, it may also be preferred to produce the extracts exclusively from flowers and / or leaves of the plant.
Hinsichtlich der erfindungsgemäß verwendbaren Pflanzenextrakte wird insbesondere auf die Extrakte hingewiesen, die in der auf Seite 44 der 3. Auflage des Leitfadens zur Inhaltsstoffdeklaration kosmetischer Mittel, herausgegeben vom Industrieverband Körperpflege- und Waschmittel e.V. (IKW), Frankfurt, beginnenden Tabelle aufgeführt sind.With regard to the plant extracts which can be used according to the invention, reference is made in particular to the extracts which are listed in the table beginning on page 44 of the 3rd edition of the guide to the declaration of ingredients of cosmetic products, published by the Industry Association for Personal Care and Detergents (IKW), Frankfurt.
Erfindungsgemäß sind vor allem die Extrakte aus Eichenrinden, Brennessel, Hamamelis, Hopfen, Kamille, Klettenwurzel, Schachtelhalm, Weißdorn, Lindenblüten, Mandel, Aloe Vera, Fichtennadel, Roßkastanie, Sandelholz, Wacholder, Kokosnuß, Mango, Aprikose, Limone, Weizen, Kiwi, Melone, Orange, Grapefruit, Salbei, Rosmarin, Birke, Malve, Wiesenschaumkraut, Quendel, Schafgarbe, Thymian, Melisse, Hauhechel, Huflattich, Eibisch, Meristem, Ginseng, Ingwerwurzel und Grünem Tee verwendbar. Bevorzugt sind die Extrakte aus Eichenrinden, Brennessel, Hamamelis, Hopfen, Kamille, Klettenwurzel, Schachtelhalm, Lindenblüten, Mandel, Aloe Vera, Kokosnuß, Mango, Aprikose, Limone, Weizen, Kiwi, Melone, Orange, Grapefruit, Salbei, Rosmarin, Birke, Wiesenschaumkraut, Quendel, Schafgarbe, Hauhechel, Meristem, Ginseng, Ingwerwurzel und Grünem Tee.According to the invention, the extracts from oak bark, nettle, witch hazel, hops, chamomile, burdock root, horsetail, hawthorn, linden flowers, almond, aloe vera, spruce needle, horse chestnut, sandalwood, juniper, coconut, mango, apricot, lime, wheat, kiwi, kiwi Melon, orange, grapefruit, sage, rosemary, birch, mallow, cuckoo flower, quendel, yarrow, thyme, lemon balm, squirrel, coltsfoot, marshmallow, meristem, ginseng, ginger root and green tea. The extracts from oak bark, nettle, witch hazel, hops, chamomile, burdock root, horsetail, linden flowers, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi, melon, orange, grapefruit, sage, rosemary, birch, Cuckoo flower, quendel, yarrow, hake, meristem, ginseng, ginger root and green tea.
Ganz besonders für die erfindungsgemäße Verwendung geeignet sind die Extrakte aus Mandel, Aloe Vera, Kokosnuß, Mango, Aprikose, Limone, Weizen, Kiwi, Melone und Grünem Tee.The extracts from almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi, melon and green tea are particularly suitable for the use according to the invention.
Als Extraktionsmittel zur Herstellung der genannten Pflanzenextrakte können Wasser, Alkohole, Wasser-Alkohol-Mischungen sowie CO2 verwendet werden. Unter den Alkoholen sind dabei niedere Alkohole wie Ethanol und Isopropanol, insbesondere aber mehrwertige Alkohole wie Ethylenglykol und Propylenglykol, sowohl als alleiniges Extraktionsmittel als auch in Mischung mit Wasser, bevorzugt. Pflanzenextrakte auf Basis von Wasser/Propylenglykol im Verhältnis 1 :10 bis 10:1 haben sich als besonders geeignet erwiesen.Water, alcohols, water-alcohol mixtures and CO 2 can be used as extractants for the production of the plant extracts mentioned. Among the alcohols, lower alcohols such as ethanol and isopropanol, but in particular polyhydric alcohols such as ethylene glycol and propylene glycol, are preferred, both as the sole extracting agent and in a mixture with water. Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
Die Pflanzenextrakte können erfindungsgemäß sowohl in reiner als auch in verdünnter Form eingesetzt werden. Sofern sie in verdünnter Form eingesetzt werden, so enthalten sie üblicherweise ca. 2 - 80 Gew.-% Aktivsubstanz und als Lösungsmittel das bei ihrer Gewinnung eingesetzte Extraktionsmittel oder Extraktionsmittelgemisch.According to the invention, the plant extracts can be used both in pure and in diluted form. If they are used in dilute form, they usually contain about 2 to 80% by weight of active substance and, as a solvent, the extractant or mixture of extractants used in their extraction.
Weiterhin kann es bevorzugt sein, in den erfindungsgemäßen Mitteln Mischungen aus mehreren, insbesondere aus zwei, verschiedenen Pflanzenextrakten einzusetzen.Furthermore, it may be preferred to use mixtures of several, in particular two, different plant extracts in the agents according to the invention.
Honigextrakte werden in analoger Weise zu den Pflanzenextrakten gewonnen und enthalten üblicherweise 1 - 10 Gew.-%, insbesondere 3 - 5 Gew.-%, Aktivsubstanz. Wasser/Propylenglykol-Mischungen können auch hier bevorzugte Extraktionsmittel sein.Honey extracts are obtained in an analogous manner to the plant extracts and usually contain 1 to 10% by weight, in particular 3 to 5% by weight, of active substance. Water / propylene glycol mixtures can also be preferred extraction agents here.
Pflanzenextrakte werden in erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,1 - 20 Gew.-%, insbesondere in Mengen von 0,2 - 8 Gew.-% eingesetzt. Mengen von 0,5 - 5 Gew.-% können ganz besonders bevorzugt sein. Diese Mengenangaben sind zum einen bezogen auf das gesamte erfindungsgemäße Mittel, zum anderen auf den Pflanzenextrakt in der Form, in der dieser dem Mittel zugegeben wird. Dabei kann es sich, wie bereits oben ausgeführt, sowohl um einen reinen Pflanzenextrakt als auch um eine Lösung mit üblicherweise 2-80 Gew.-% Aktivsubstanz handeln.Plant extracts are used in agents according to the invention preferably in amounts of 0.1-20% by weight, in particular in amounts of 0.2-8% by weight. Amounts of 0.5-5% by weight can be very particularly preferred. These quantities are on the one hand based on the total agent according to the invention, on the other hand on the plant extract in the form in which it is added to the agent. As already stated above, this can be both a pure plant extract and a solution with usually 2-80% by weight of active substance.
Bezüglich der Mengenangaben und der Konfektionierungsform der Honigextrakte gilt das für Pflanzenextrakte gesagte, wobei Extrakte mit 0,01-10 Gew.-%, insbesondere 3-5 Gew.-%, Aktivsubstanz bevorzugt sein können.With regard to the quantities and the form of the honey extracts, what has been said for plant extracts applies, extracts with 0.01-10% by weight, in particular 3-5% by weight, of active substance being preferred.
Weiterhin enthalten die erfindungsgemäßen Zubereitungen bevorzugt noch einen Filmbildner. Als Filmbildner kommen vor allem ionische und insbesondere nichtionogene Polymere in Betracht.The preparations according to the invention preferably also contain a film former. Ionic and in particular nonionic polymers are particularly suitable as film formers.
Bevorzugte nichtionische Polymere sind Polyvinylpyrrolidon und Vinylpyrrolidon/Vinyl- acetat-Copolymere (beispielsweise die Produkte Luviskol®K 30, K90, NA 64 und VA 37) und Polysiloxane (wie beispielsweise die Handelsprodukte Dow Corning 345, 190, 193, 200, 245, 246, 1401 und 1403).Preferred nonionic polymers are polyvinyl pyrrolidone and vinyl pyrrolidone / vinyl acetate copolymers (for example the products Luviskol ® K 30, K90, NA 64 and VA 37), and polysiloxanes (such as the commercial products Dow Corning 345, 190, 193, 200, 245, 246 , 1401 and 1403).
Erfindungsgemäß bevorzugte kationische Polymere sind quaternisierte Celluloseether wie beispielsweise das Handelsprodukt Polymer JR®400, Polysiloxane mit quaternären Gruppen wie Dow Corning DC®929, Dimethyldiallylammoniumchlorid-Polymere wie Merquat®100, Acrylamid-Dimethyldiallylammoniumchlorid-Copolymere wie Merquat® 550, mit Diethylsulfat quaternierte Dimethylaminoethylmethacrylat-Vinylpyrrolidon- Copolymere wie Gafquat® 734 und 755, Vinylpyrrolidon-Imidazoliniummethochlorid- Copolymere wie die Handelsprodukte der Luviquat®-Serie sowie quaternierter Polyvinylalkohol.According to the invention preferred cationic polymers are quaternized cellulose ethers such as for example the commercial product Polymer JR ® 400, polysiloxanes with quaternary groups such as Dow Corning DC ® 929, dimethyldiallylammonium chloride polymers such as Merquat ® 100, acrylamide-dimethyl diallyl ammonium chloride copolymers, such as Merquat ® 550, quaternized with diethyl sulfate dimethylaminoethyl Vinylpyrrolidone copolymers such as Gafquat ® 734 and 755, vinylpyrrolidone-imidazolinium methochloride copolymers such as the commercial products of the Luviquat ® series and quaternized polyvinyl alcohol.
Geeignete zwitterionische und amphotere Polymere sind beispielsweise Acrylamido- propyl-trimethylammoniumchlorid/Acrylat-Copolymere, Octylacrylamid/Methylmeth- acrylat/tert.Butylaminoethylmethacrylat/2-Hydroxypropylmethacrylat-Copolymere wie das Handelsprodukt Amphomer® sowie Dimethyldiallylammoniumchlorid-Acrylsäure- Copolymere wie das Handelsprodukt Merquat® 280. Erfindungsgemäß bevorzugte anionische Polymere sind Polyacrylsäuren und vernetzte Polyacrylsäuren wie beispielsweise die Handelsprodukte der Carbopol®-Serie, insbesondere Carbopol® ETD 2020, Vinylacetat/Crotonsäure-Copolymere und -Ter- polymere wie die Produkte der Luviset®-Serie, Vinylpyrrolidon/Vinylacrylat- Copolymere, Vinylacetat/Butylmaleat/Isobornylacrylat-Copolymere, Methylvinyl- ether/Maleinsäure-anhydrid-Copolymere wie die Produkte der Gantrez®-Serie und Acryl- säure/Ethylacrylat/N-tert.Butylacrylamid-Te olymere.Suitable zwitterionic and amphoteric polymers are, for example, acrylamido- propyl-trimethylammonium chloride / acrylate copolymers, octylacrylamide / acrylate Methylmeth- / tert.Butylaminoethylmethacrylat / 2-hydroxypropyl methacrylate copolymers such as the product Amphomer ® and dimethyl diallyl ammonium chloride-acrylic acid copolymers such as the product Merquat ® 280th Anionic polymers preferred according to the invention are polyacrylic acids and crosslinked polyacrylic acids such as, for example, the commercial products of the Carbopol ® series, in particular Carbopol ® ETD 2020, vinyl acetate / crotonic acid copolymers and terpolymers such as the products of the Luviset ® series, vinylpyrrolidone / vinyl acrylate copolymers, Vinyl acetate / butyl maleate / isobornyl acrylate copolymers, methyl vinyl ether / maleic anhydride copolymers such as the products of the Gantrez ® series and acrylic acid / ethyl acrylate / N-tert-butyl acrylamide te olymers.
Die erfmdungsgemäßen Zubereitungen können auf wäßriger, wäßrig-alkoholischer oder alkoholischer Basis formuliert sein. Als Alkohole kommen dabei insbesondere niedere Alkohole wie Ethanol und Isopropanol in Betracht. Wäßrig-alkoholische Grundlagen können dabei Wasser und Alkohol bevorzugt in einem Verhältnis von 1 :5 bis 5:1 enthalten.The preparations according to the invention can be formulated on an aqueous, aqueous-alcoholic or alcoholic basis. Lower alcohols such as ethanol and isopropanol are particularly suitable as alcohols. Aqueous-alcoholic bases can preferably contain water and alcohol in a ratio of 1: 5 to 5: 1.
Die erfindungsgemäße Wirkstoffkombination kann sowohl in Form einer separaten Formulierung oder als zusätzliche Komponente in anderen Mitteln auf das Haar aufgebracht werden.The active ingredient combination according to the invention can be applied to the hair both in the form of a separate formulation or as an additional component in other agents.
Gemäß einer ersten Ausführungsform werden die erfindungsgemäßen Zubereitungen als Haartonic, Haarspülung oder als Haarkur formuliert. Haartonics verbleiben üblicherweise bis zur nächsten Haarbehandlung, z.B. der täglichen Haarwäsche, auf dem Haar. Haarspülungen werden in der Regel so formuliert, daß ein Ausspülen der Wirkstoffe nach der gewünschten Einwirkzeit mit Wasser oder einem zumindest überwiegend wasserhaltigen Mittel vorgesehen ist. Die Kontaktzeit mit dem Haar ist in der Regel kurz. Haarkuren enthalten die Wirkstoffkombination in einer höheren Konzentration als Haarspülungen und sind zur intensiven Behandlung des Haares und gegebenenfalls der Kopfhaut vorgesehen. Die Einwirkzeit kann kurz sein, beispielsweise in der Größenordnung der Einwirkzeit von Haarspülungen, sie kann jedoch auch je nach Grad der Schädigung des Haares bis zu 20 Minuten betragen. Auch die erfindungsgemäßen Haarkuren können nach Ablauf dieser Einwirkzeit mit Wasser oder einem zumindest überwiegend wasserhaltigen Mittel ausgespült werden; sie können jedoch auch auf dem Haar belassen werden. Diese Mittel können in einer bevorzugten Variante als Schaumaerosole formuliert werden. Dazu können die Mittel Treibgase enthalten. Bevorzugt ist in dieser Variante jedoch die Formulierung als Pumpspray mit Luft als Treibmittel.According to a first embodiment, the preparations according to the invention are formulated as a hair tonic, hair conditioner or as a hair treatment. Hair tonics usually remain on the hair until the next hair treatment, e.g. daily shampooing. Hair rinses are generally formulated in such a way that the active ingredients are rinsed out with water or an at least predominantly water-containing agent after the desired exposure time. The contact time with the hair is usually short. Hair treatments contain the active ingredient combination in a higher concentration than hair rinses and are intended for intensive treatment of the hair and possibly the scalp. The exposure time can be short, for example in the order of the exposure time of hair rinses, but it can also be up to 20 minutes depending on the degree of damage to the hair. After this exposure time, the hair treatments according to the invention can also be rinsed out with water or an at least predominantly water-containing agent; but you can also on the Hair left. In a preferred variant, these agents can be formulated as foam aerosols. For this purpose, the agents can contain propellant gases. In this variant, however, the formulation as a pump spray with air as the blowing agent is preferred.
Gemäß weiteren Ausfuhrungsformen kann es sich bei den erfindungsgemäßen Mitteln beispielsweise um reinigende Mittel wie Shampoos, festigende Mittel wie Haarfestiger, Haarsprays und Fönwellen, dauerhafte Verformungsmittel wie Dauerwell- und - fixiermittel, farbverändernde Mittel wie Blondiermittel, Oxidationsfärbemittel und Tönungsmittel auf Basis direktziehender Farbstoffe, Haarwässer und Haarspitzenfluids handeln.According to further embodiments, the agents according to the invention can include, for example, cleaning agents such as shampoos, setting agents such as hair setting agents, hair sprays and blow dryer waves, permanent shaping agents such as permanent wave and fixing agents, color-changing agents such as bleaching agents, oxidation dyes and tinting agents based on direct dyes, hair lotions and Trade tip fluids.
Zur Behandlung der Haut können die erfindungsgemäßen Zubereitungen beispielsweise als Hautpflegemittel und Hautreinigungsmittel konfektioniert werden. Insbesondere bei Hautbehandlungsmitteln sind solche Zubereitungen erfindungsgemäß bevorzugt, die nach der Applikation auf dem Körper, hier der Haut, verbleiben.For the treatment of the skin, the preparations according to the invention can be packaged, for example, as skin care agents and skin cleansers. Particularly in the case of skin treatment agents, those preparations are preferred according to the invention which remain on the body, here the skin, after application.
Entsprechend können die Zubereitungen als Lösungen, Öl-in-Wasser-Emulsionen, Wasser-in-Öl-Emulsionen, Nanoemulsionen, Mikroemulsionen, insbesondere solche vom PIT-Typ, Gele, Cremes, Aerosole oder Lotionen formuliert werden. Die Zubereitungen können auch in verkapselter Form, beispielsweise in Gelatine oder Polyvinylalkohol, sowie in Form von Liposomen, z.B. mit Lecithin, konfektioniert werden. Sofern diese Zubereitungen Komponenten enthalten, die zusammen mit einem oder mehreren Bestandteil(en) der erfindungsgemäßen Wirkstoffkombination nicht lagerstabil formuliert werden können, ist es, wie bereits oben ausgeführt, möglich, diese erfindungsgemäße Wirkstoffkomponente oder Wirkstoffkombination in Form einer seperaten Formulierung zu konfektionieren und der Zubereitung erst unmittelbar vor der Anwendung zuzumischen.Accordingly, the preparations can be formulated as solutions, oil-in-water emulsions, water-in-oil emulsions, nanoemulsions, microemulsions, in particular those of the PIT type, gels, creams, aerosols or lotions. The preparations can also be in encapsulated form, for example in gelatin or polyvinyl alcohol, as well as in the form of liposomes, e.g. with lecithin. If these preparations contain components which, together with one or more constituents of the active compound combination according to the invention, cannot be formulated in a stable manner, it is possible, as already explained above, to assemble this active compound component or active compound combination according to the invention in the form of a separate formulation and the preparation only mix immediately before use.
Entsprechend der Art des gewählten Mittels können die erfindungsgemäßen Zubereitungen die in diesen Mitteln üblichen, weiteren Bestandteile enthalten. Weitere übliche Bestandteile der erfindungsgemäßen Zubereitungen können somit sein: anionische Tenside wie insbesondere Alkylsulfate, Alkylpolyglykolethersulfate und Ethercarbonsäuren mit 10 bis 18 C- Atomen in der Alkylgruppe und bis zu 12 Glykolethergruppen im Molekül, sowie Sulfobemsteinsäuremono- und -dialkylester mit 8 bis 18 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremono-alkyl- polyoxyethylester mit 8 bis 18 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen. nichtionogene Tenside wie insbesondere Anlagerungsprodukte von 2 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 C-Atomen, an Fettsäuren mit 12 bis 22 C-Atomen, an Alkylphenole mit 8 bis 15 C- Atomen in der Alkylgruppe sowie an entsprechende Fettsäureamide und Fettamine, Cι -C22-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Glycerin, C8-C -Alkylmono- und -oligoglycoside und deren ethoxylierte Analoga, Fettsäure-N-alkylglucamide, Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl, Polyolfettsäureester, Zuckerester, Sorbitanester und Polysorbate. Sofern die nichtionischen Tenside Poly- glycoletherketten enthalten, können sie eine konventionelle oder eingeengte Homologenverteilung aufweisen. zwitterionische Tenside, insbesondere die sogenannten Betaine wie die N-Alkyl- N,N-dimethylammonium-glycinate, beispielsweise das Kokosalkyl-dimethyl- ammonium-glycinat, N-Acyl-aminopropyl-N,N-dimethylammoniumglycinate, beispielsweise das Kokosacylaminopropyl-dimethylammoniumglycinat, und 2-Alkyl- 3-carboxylmethyl-3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe sowie das Kokosacylaminoethylhydroxyethylcarb- oxymethylglycinat. ampholytische Tenside wie N-Alkylglycine, N-Alkylpropionsäuren, N-Alkylamino- buttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxyethyl-N-alkylamidopro- pylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkylaminopropionsäuren und Alkylaminoessigsäuren mit jeweils etwa 8 bis 18 C-Atomen in der Alkylgruppe, kationische Tenside vom Typ der quartären Ammoniumverbindungen, bevorzugt Ammoniumhalogenide, insbesondere Chloride und Bromide, wie Alkyltrimethyl- ammoniumchloride, Dialkyldimethylammoniumchloride und Trialkylme- thylammoniumchloride, z. B. Cetyltrimethylammoniumchlorid, Stearyltri- methylammoniumchlorid, Distearyldimethylammoniumchlorid, Lauryldimethyl- ammoniumchlorid, Lauryldimethylbenzylammoniumchlorid und Tricetylmethyl- ammoniumchlorid, Behenyltrimethylammoniummethosulfat sowie die unter den LNCI-Bezeichnungen Quaternium-27 und Quaternium-83 bekannten Imidazolium- Verbindungen, vom Typ der Esterquats, beispielsweise auf Basis von Trietha- nolamin, Diethanolalkylaminen oder 1,2-Dihydroxypropyldialkylaminen einerseits und Fettsäuren wie Capronsäure, Caprylsäure, Caprinsäure, Laurinsäure, Myristinsäure, Palmitinsäure, Isostearinsäure, Stearinsäure, Ölsäure, Elaidinsäure, Arachinsäure, Behensäυre und Erucasäure oder deren technische Mischungen, wie sie beispielweise bei der Druckspaltung natürlicher Fette und Öle anfallen, wie beispielsweise die unter den Warenzeichen Dehyquart® und Armocare® erhältlichen Produkte sowie vom Typ der Alkylamidoamine wie das unter der Bezeichnung Tegoamid® S 18 im Handel erhältliche Stearamidopropyldimethylamin, symmetrische und unsymmetrische, lineare und verzweigte Dialkylether mit insgesamt zwischen 12 bis 36 C-Atomen, insbesondere 12 bis 24 C-Atomen, sie beispielsweise Di-n-octylether, Di-n-decylether, Di-n-nonylether, Di-n- undecylether und Di-n-dodecylether, n-Hexyl-n-octylether, n-Octyl-n-decylether, n- Decyl-n-undecylether, n-Undecyl-n-dodecylether und n-Hexyl-n-Undecylether sowie Di-tert-butylether, Di-iso-pentylether, Di-3-ethyldecylether, tert.-Butyl-n- octylether, iso-Pentyl-n-octylether und 2-Methyl-pentyl-n-octylether, Entschäumer wie Silikone,Depending on the type of agent selected, the preparations according to the invention may contain the further constituents customary in these agents. Further common constituents of the preparations according to the invention can thus be: anionic surfactants such as, in particular, alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids with 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, and also sulfosuccinic acid and dialkyl esters with 8 to 18 carbon atoms in the alkyl group and sulfosuccinic acid mono-alkyl polyoxyethyl ester 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups. nonionic surfactants such as, in particular, adducts of 2 to 30 mol of ethylene oxide and / or 0 to 5 mol of propylene oxide with linear fatty alcohols with 8 to 22 C atoms, with fatty acids with 12 to 22 C atoms, with alkylphenols with 8 to 15 C atoms in the alkyl group and corresponding fatty acid amides and fatty amines, -C 22 -C fatty acid mono- and diesters of adducts of 1 to 30 mol ethylene oxide with glycerol, C 8 -C alkyl mono- and oligoglycosides and their ethoxylated analogs, fatty acid N-alkylglucamides , Addition products of 5 to 60 moles of ethylene oxide with castor oil and hardened castor oil, polyol fatty acid esters, sugar esters, sorbitan esters and polysorbates. If the nonionic surfactants contain polyglycol ether chains, they can have a conventional or narrow homolog distribution. zwitterionic surfactants, in particular the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyl dimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyl dimethylammonium glycinate, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate. ampholytic surfactants such as N-alkylglycine, N-alkylpropionic acid, N-alkylamino-butyric acid, N-alkyliminodipropionic acid, N-hydroxyethyl-N-alkylamido propylglycine, N-alkyltaurine, N-alkyl sarcosine, 2-alkylaminopropionic acid and alkylaminoacetic acid each with about 8 to 18 C atoms in the alkyl group, cationic surfactants of the quaternary ammonium compound type, preferably ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, for. B. cetyltrimethylammonium chloride, stearyltri- methylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride, behenyltrimethylammonium methosulfate as well as the imidazolium quaternium or triethylamine known from LNCI names, e.g. , 2-Dihydroxypropyldialkylaminen on the one hand and fatty acids such as caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, isostearic acid, stearic acid, oleic acid, elaidic acid, arachidic acid, behenic acid and erucic acid or their technical mixtures, as they occur, for example, in the pressure and oil splitting of natural fats such as those available under the trademark Dehyquart® ® and Armocare® ® available products as well as the type of Alkylamidoamine as Stearamidopropyldimethy obtainable under the name Tegoamid ® S 18. trade lamin, symmetrical and asymmetrical, linear and branched dialkyl ethers with a total of between 12 to 36 carbon atoms, in particular 12 to 24 carbon atoms, for example di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di- n-undecyl ether and di-n-dodecyl ether, n-hexyl-n-octyl ether, n-octyl-n-decyl ether, n-decyl-n-undecyl ether, n-undecyl-n-dodecyl ether and n-hexyl-n-undecyl ether as well Di-tert-butyl ether, di-isopentyl ether, di-3-ethyl decyl ether, tert-butyl-n-octyl ether, isopentyl-n-octyl ether and 2-methyl-pentyl-n-octyl ether, defoamers such as silicones,
Verdickungsmittel wie Agar-Agar, Guar-Gum, Alginate, Xanthan-Gum, Gelatine, Pektine, Hydroxyethylcellulose sowie Polyacrylamide und deren Copolymere, Strukturanten wie Maleinsäure,Thickening agents such as agar agar, guar gum, alginates, xanthan gum, gelatin, pectins, hydroxyethyl cellulose and polyacrylamides and their copolymers, structurants such as maleic acid,
Mono-, Di- und Oligosaccharide, wie beispielsweise Glucose, Galactose, Fructose, Fruchtzucker und Lactose, Ceramide, pflanzliche Öle wie Jojobaöl, Sonnenblumenöl, Orangenöl, Mandelöl, Weizenkeimöl und Pfirsichkernöl sowie Paraffinöle, gesättigte und ungesättigte, lineare und verzweigte Fettalkohole mit 8 bis 22 C- Atomen sowie deren Mischungen, die durch Reduktion natürlich vorkommender Triglyceride wie Rindertalg, Palmöl, Erdnußöl, Rüböl, Baumwollsaatöl, Sojaöl,Mono-, di- and oligosaccharides, such as glucose, galactose, fructose, fructose and lactose, ceramides, vegetable oils such as jojoba oil, sunflower oil, orange oil, almond oil, wheat germ oil and peach seed oil as well as paraffin oils, saturated and unsaturated, linear and branched fatty alcohols with 8 to 22 carbon atoms and their mixtures, which are reduced by naturally occurring Triglycerides such as beef tallow, palm oil, peanut oil, rape oil, cottonseed oil, soybean oil,
Sonnenblumenöl und Leinöl entstehen,Sunflower oil and linseed oil are produced
Monoester der Fettsäuren mit Alkoholen mit 6 bis 24 C-Atomen. haarkonditionierende Verbindungen vom Typ der Phospholipide, beispielsweiseMonoesters of fatty acids with alcohols with 6 to 24 carbon atoms. hair conditioning compounds of the phospholipid type, for example
Sojalecithin, Ei-Lecithin und Kephaline,Soy lecithin, egg lecithin and cephaline,
Parfümöle, Dimethylisosorbid und Cyclodextrine,Perfume oils, dimethyl isosorbide and cyclodextrins,
Lösungsvermittler, wie Ethanol, Isopropanol, Ethylenglykol, Propylenglykol,Solubilizers, such as ethanol, isopropanol, ethylene glycol, propylene glycol,
Glycerin und Diethylenglykol,Glycerin and diethylene glycol,
Farbstoffe zum Anfärben des Mittels,Dyes for coloring the agent,
Antischuppenwirkstoffe wie Piroctone Olamine, Zink Omadine und Climbazol, weitere Substanzen zur Einstellung des pH- WertesAnti-dandruff agents such as piroctone olamine, zinc omadine and climbazole, other substances for adjusting the pH value
Wirkstoffe wie Allantoin, Pyrrolidoncarbonsäuren und Bisabolol,Active ingredients such as allantoin, pyrrolidone carboxylic acids and bisabolol,
Lichtschutzmittel,Light stabilizers,
Konsistenzgeber wie Zuckerester, Polyolester oder Polyolalkylether,Consistency enhancers such as sugar esters, polyol esters or polyol alkyl ethers,
Fette und Wachse, wie Walrat, Bienenwachs, Montanwachs und Paraffine,Fats and waxes such as walrus, beeswax, montan wax and paraffins,
Fettsäurealkanolamide,Fatty acid alkanolamides,
Trübungsmittel wie Latex, Styrol/PVP- und Styrol/Acrylamid-Copolymere,Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers,
Perlglanzmittel wie Ethylenglykolmono- und -distearat sowie PEG-3-distearat,Pearlescent agents such as ethylene glycol mono- and distearate and PEG-3 distearate,
Komplexbildner wie EDTA, NTA, ß-Alanindiessigsäure und Phosphonsäuren, direktziehende Farbstoffe sogenannte Kuppler- und Entwicklerkomponenten als Oxidationsfarbstoffvorpro- dukte,Complexing agents such as EDTA, NTA, ß-alaninediacetic acid and phosphonic acids, direct dyes so-called coupler and developer components as oxidation dye precursors,
Reduktionsmittel wie z.B. Thioglykolsäure und deren Derivate, Thiomilchsäure,Reducing agents such as Thioglycolic acid and its derivatives, thiolactic acid,
Cysteamin, Thioäpfelsäure und α-Mercaptoethansulfonsäure,Cysteamine, thio malic acid and α-mercaptoethanesulfonic acid,
Oxidationsmittel wie Wasserstoffperoxid, Kaliumbromat und Natriumbromat,Oxidizing agents such as hydrogen peroxide, potassium bromate and sodium bromate,
Treibmittel wie Propan-Butan-Gemische, N2O, Dimethylether, CO2, N2 und Luft sowieBlowing agents such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 , N 2 and air as well
Antioxidantien.Antioxidants.
Bezüglich weiterer Verbindungen wird auf die dem Fachmann bekannten Handbücher, z.B. K. Schrader, Grundlagen und Rezepturen der Kosmetika, 2. Auflage, Hüthig Buch Verlag, Heidelberg, 1989, verwiesen. Der pH- Wert der erfindungsgemäßen Zubereitungen kann prinzipiell zwischen 4,5 und 7 liegen, wobei der Fachmann ihm bekannte Instabilitäten, beispielsweise des Grundkörpers Panthenol im alkalischen Milieu, berücksichtigen wird. Der pH- Wert der erfindungsgemäßen Mittel liegt bevorzugt zwischen 6 und 6,5. Zur Einstellung dieses pH- Wertes kann praktisch jede für kosmetische Zwecke verwendbare Säure verwendet werden. Üblicherweise werden Genußsäuren verwendet. Unter Genußsäuren werden solche Säuren verstanden, die im Rahmen der üblichen Nahrungsaufnahme aufgenommen werden und positive Auswirkungen auf den menschlichen Organismus haben. Genußsäuren sind beispielsweise Essigsäure, Milchsäure, Weinsäure, Zitronensäure, Äpfelsäure, Ascorbinsäure und Gluconsäure. Im Rahmen der Erfindung ist die Verwendung von Milchsäure und Zitronensäure besonders bevorzugt.With regard to other compounds, reference is made to the manuals known to the person skilled in the art, for example K. Schrader, Fundamentals and Recipes for Cosmetics, 2nd edition, Hüthig Buch Verlag, Heidelberg, 1989. The pH of the preparations according to the invention can in principle be between 4.5 and 7, the instabilities known to the person skilled in the art, for example the base body panthenol in an alkaline environment, being taken into account. The pH of the agents according to the invention is preferably between 6 and 6.5. Virtually any acid that can be used for cosmetic purposes can be used to adjust this pH. Food acids are usually used. Edible acids are understood to mean those acids that are ingested as part of normal food intake and have positive effects on the human organism. Examples of edible acids are acetic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid and gluconic acid. In the context of the invention, the use of lactic acid and citric acid is particularly preferred.
Weitere Gegenstände der Erfindung sind die Verwendung einer Wirkstoffkombination, bestehend aus Biotin und mindestens einem Glykoprotein, zur Behandlung von menschlicher Haut und menschlichen Haaren sowie die Verwendung dieser Wirkstoffkombination zur Erhöhung der Proteinproduktion in menschlichen Zellen. Further objects of the invention are the use of a combination of active ingredients, consisting of biotin and at least one glycoprotein, for the treatment of human skin and hair, and the use of this combination of active ingredients for increasing protein production in human cells.
BeispieleExamples
1. Bestimmung der Proteinproduktion in menschlichen Zellen1. Determination of protein production in human cells
Normale humane Keratinozyten wurden nach Angaben des Lieferanten (PROMO CELL) in 24-Well-Schalen in Kultur genommen (5 % CO2, 37 °C, gesättigte Wasserdampf- Atmosphäre) und in Subkonfluenz mit den im Medium gelösten Substanzen versetzt. Nach 24 Stunden wurde das Gesamtprotein nach Lowra bestimmt (n= 6 Wells). Das Gesamtprotein ist ein Maß für die erzeugte Biomasse, die als Kennzahl für die Vitalität der Zelle angesehen werden kann.According to the supplier (PROMO CELL), normal human keratinocytes were taken in culture in 24-well dishes (5% CO 2 , 37 ° C, saturated water vapor atmosphere) and the substances dissolved in the medium were added in subconfluence. After 24 hours, the Lowra total protein was determined (n = 6 wells). The total protein is a measure of the biomass produced, which can be seen as a key figure for the vitality of the cell.
Die untersuchten Zusammensetzungen sowie die erhaltenen Werte für die Proteinbildung sind in der folgenden Tabelle zusammengestellt. Die Mischung VI stellt eine um den Faktor 10 verdünnte physiologische Kochsalz-Lösung dar. Alle Mengenangaben sind, soweit nicht anders vermerkt, Gewichts-Teile.The compositions examined and the values obtained for protein formation are summarized in the following table. Mixture VI is a physiological saline solution diluted by a factor of 10. Unless otherwise noted, all quantities are parts by weight.
VI V2 V3 ElVI V2 V3 El
Komponenten:Components:
• Natriumchlorid ι,09 0,09 0,09 0,09Sodium chloride 09.09 0.09 0.09
• Biotin - 0,00001 0,00001• Biotin - 0.00001 0.00001
• Phytodermine - 0,5 0,5Phytodermine - 0.5 0.5
• Wasser ad 100 >• Water ad 100>
Gebildete Proteinmenge [%] 100 98 99 138Amount of protein formed [%] 100 98 99 138
1 Proteine aus der Sojabohne (Hydroxyprolin-reiche Glykoproteine als Extensine, Arabinogalactane als Proteoglykan-Äquivalenten und Prolin-reiche Glykoproteine aus der Pflanzenmatrix der Sojabohne in natürlicher Verteilung; INCI-Bezeichnung: Soybean (Glycine Soja) Protein) (CLR Chemisches Laboratorium Dr. Kurt Richter) 2. Ausführungsbeispiele1 Proteins from soybean (hydroxyproline-rich glycoproteins as extensines, arabinogalactans as proteoglycan equivalents and proline-rich glycoproteins from the plant matrix of soybeans in a natural distribution; INCI name: Soybean (Glycine Soybean Protein)) (CLR Chemical Laboratory Dr. Kurt Judge) 2. Embodiments
Alle Mengenangaben sind, soweit nicht anders vermerkt, Gewichtsteile.Unless otherwise noted, all quantities are parts by weight.
2.1 Haartonic2.1 hair tonic
Biotin 0,005Biotin 0.005
Phytodermin® 0,5Phytodermin ® 0.5
D-Panthenol 0,2D-panthenol 0.2
Gluadin® W 202 0,1Gluadin ® W 20 2 0.1
Cremophor®RH 403 0,3Cremophor ® RH 40 3 0.3
Parfümöl 0,15Perfume oil 0.15
Ethanol 30,0Ethanol 30.0
Wasser ad 100Water ad 100
Weizenproteinhydrolysat (20 % Aktivsubstanz in Wasser; INCI-Bezeichnung: Aqua (and) Hydrolized Wheat Protein (and) Sodium Benzoate (and) Phenoxyethanol (and) Methylparaben (and) Propylparaben) (HENKEL)Wheat protein hydrolyzate (20% active substance in water; INCI name: Aqua (and) Hydrolized Wheat Protein (and) Sodium Benzoate (and) Phenoxyethanol (and) Methylparaben (and) Propylparaben) (HENKEL)
3 hydriertes Rizinusöl + 45 EO (INCI-Bezeichnung:PEG-40 Hydrogenated Castor Oil) (BASF)3 hydrogenated castor oil + 45 EO (INCI name: PEG-40 Hydrogenated Castor Oil) (BASF)
2.2 Haartonic2.2 hair tonic
Biotin 0,003Biotin 0.003
Phytodermin® 0,3Phytodermin ® 0.3
D-Panthenol 0,1D-panthenol 0.1
Honig-Extrakt HS 2660 G4 0,2Honey extract HS 2660 G 4 0.2
Gluadin® W 405 0,1Gluadin ® W 40 5 0.1
Carbopol® ETD 20206 0,1 Cremophor®RH 40 0,3Carbopol ® ETD 2020 6 0.1 Cremophor ® RH 40 0.3
Parfümöl 0,15 iso-Propanol 35,0 Wasser ad 100 Honig-Extrakt (12-15 % Aktivsubstanz; INCI-Bezeichnung: Mel) (GRAUPerfume oil 0.15 isopropanol 35.0 water ad 100 Honey extract (12-15% active substance; INCI name: Mel) (GRAY
AROMATICS)AROMATICS)
Weizenproteinhydrolysat (40 % Aktivsubstanz in Wasser; INCI-Bezeichnung:Wheat protein hydrolyzate (40% active ingredient in water; INCI name:
Aqua (and) Hydrolized Wheat Protein (and) Sodium Benzoate (and)Aqua (and) Hydrolized Wheat Protein (and) Sodium Benzoate (and)
Phenoxyethanol (and) Methylparaben (and) Propylparaben) (HENKEL)Phenoxyethanol (and) methylparaben (and) propylparaben) (HENKEL)
Polyacrylsäure-Copolymer (INCI-Bezeichnung: Acrylates/C 10-30 Alkyl AcrylatePolyacrylic acid copolymer (INCI name: Acrylates / C 10-30 alkyl acrylates
Crosspolymer) (GOODRICH) Cross polymer) (GOODRICH)

Claims

Patentansprüche claims
1. Zubereitung zur Behandlung der menschlichen Haut und der menschlichen Haare, dadurch gekennzeichnet, daß sie eine Wirkstoffkombination, bestehend aus1. Preparation for the treatment of human skin and human hair, characterized in that it is an active ingredient combination consisting of
Biotin und mindestens einem Glykoprotein enthält.Contains biotin and at least one glycoprotein.
2. Zubereitung nach Anspruch 1, dadurch gekennzeichnet, daß es sich um ein pflanzliches Glykoprotein handelt.2. Preparation according to claim 1, characterized in that it is a vegetable glycoprotein.
3. Zubereitung nach Anspruch 2, dadurch gekennzeichnet, daß das Glykoprotein aus einer primären Pflanzenzellwand stammt.3. Preparation according to claim 2, characterized in that the glycoprotein comes from a primary plant cell wall.
4. Zubereitung einem der Ansprüche 2 oder 3, dadurch gekennzeichnet, daß das Glykoprotein ausgewählt ist aus den Glykoproteinen von Sojabohne, Reis, Hafer, Weizen, Kartoffel, Pfirsich, Mandeln, Pilze und Erbsen.4. Preparation according to one of claims 2 or 3, characterized in that the glycoprotein is selected from the glycoproteins of soybean, rice, oats, wheat, potatoes, peaches, almonds, mushrooms and peas.
5. Zubereitung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß der Kohlenhydratanteil des Glykoproteins ausgewählt ist aus Galactose, Arabinose, Mannose, Glucose und Fucose.5. Preparation according to one of claims 1 to 4, characterized in that the carbohydrate portion of the glycoprotein is selected from galactose, arabinose, mannose, glucose and fucose.
6. Zubereitung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß das Glykoprotein in einer Menge von 0,0001 - 5 Gew.-%, bezogen auf die gesamte Zubereitung, enthalten ist.6. Preparation according to one of claims 1 to 5, characterized in that the glycoprotein is contained in an amount of 0.0001 - 5 wt .-%, based on the entire preparation.
7. Zubereitung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, daß das Biotin in einer Menge von 0,000001 - 0,5 Gew.-% enthalten ist.7. Preparation according to one of claims 1 to 6, characterized in that the biotin is contained in an amount of 0.000001 - 0.5 wt .-%.
8. Zubereitung nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß sie weiterhin ein Penetrationshilfsmittel enthält. 8. Preparation according to one of claims 1 to 7, characterized in that it further contains a penetration aid.
. Zubereitung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß sie weiterhin ein Proteinhydrolysat enthält.. Preparation according to one of claims 1 to 8, characterized in that it further contains a protein hydrolyzate.
10. Zubereitung nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß sie weiterhin ein Vitamin, ausgewählt aus Panthenol, Tocopherol und Vitamin A sowie deren Vorstufen und Derivaten, enthält.10. Preparation according to one of claims 1 to 9, characterized in that it further contains a vitamin selected from panthenol, tocopherol and vitamin A and their precursors and derivatives.
11. Zubereitung nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, daß sie weiterhin einen Pflanzen- oder Honigextrakt enthält.11. Preparation according to one of claims 1 to 10, characterized in that it further contains a plant or honey extract.
12. Zubereitung nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß sie weiterhin einen Filmbildner enthält.12. Preparation according to one of claims 1 to 11, characterized in that it further contains a film former.
13. Zubereitung nach einem der Ansprüche 1 bis 12, dadurch gekennzeichnet, daß sie nach der Applikation auf dem Haar oder der Haut verbleibt.13. Preparation according to one of claims 1 to 12, characterized in that it remains on the hair or skin after application.
14. Verwendung einer Wirkstoffkombination, bestehend aus14. Use of an active ingredient combination consisting of
Biotin und mindestens einem Glykoprotein zur Behandlung von menschlicher Haut und menschlichen Haaren.Biotin and at least one glycoprotein for the treatment of human skin and hair.
15. Verwendung einer Wirkstoffkombination, bestehend aus15. Use of an active ingredient combination consisting of
Biotin und mindestens einem Glykoprotein zur Erhöhung der Proteinproduktion in menschlichen Zellen. Biotin and at least one glycoprotein to increase protein production in human cells.
PCT/EP1999/003362 1998-05-27 1999-05-15 Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination WO1999060989A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99953283A EP1079795A2 (en) 1998-05-27 1999-05-15 Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
AU42625/99A AU4262599A (en) 1998-05-27 1999-05-15 Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
CA002333544A CA2333544A1 (en) 1998-05-27 1999-05-15 Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
JP2000550450A JP2002516263A (en) 1998-05-27 1999-05-15 Formulations containing active ingredient combinations for caring for human skin and hair, and use of the active ingredient combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998123552 DE19823552A1 (en) 1998-05-27 1998-05-27 Preparation for the treatment of human skin and human hair with a special combination of active ingredients and use of this combination of active ingredients
DE19823552.6 1998-05-27

Publications (2)

Publication Number Publication Date
WO1999060989A2 true WO1999060989A2 (en) 1999-12-02
WO1999060989A3 WO1999060989A3 (en) 2000-03-02

Family

ID=7868995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003362 WO1999060989A2 (en) 1998-05-27 1999-05-15 Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination

Country Status (6)

Country Link
EP (1) EP1079795A2 (en)
JP (1) JP2002516263A (en)
AU (1) AU4262599A (en)
CA (1) CA2333544A1 (en)
DE (1) DE19823552A1 (en)
WO (1) WO1999060989A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068040A2 (en) * 2000-03-17 2001-09-20 L'oreal The use of plant extracts and sugars to protect keratinous tissue
WO2001089459A2 (en) * 2000-05-23 2001-11-29 L'oreal S.A. The use of plant extracts in a cosmetic composition to protect keratinous fibers
FR2824476A1 (en) * 2001-05-14 2002-11-15 Clarins Lab New composition comprising at least one colloidal glycoprotein complex and at least one Morera fluviatilis extract, for protecting the skin against the effects of low temperatures
GB2402676B (en) * 2003-06-13 2007-11-21 Coletica Cosmetic use by topical application of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of skin elastic fibres
US8691194B2 (en) 2002-12-12 2014-04-08 R.B.T (Rakuto Bio Technologies) Ltd. Methods of producing lignin peroxidase and its use in skin and hair lightening
DE202016003916U1 (en) 2015-06-29 2016-10-11 Hans Werner Bierganns emulsion

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1318784A1 (en) * 2000-09-11 2003-06-18 Industria E Comércio de Cosméticos Natura Ltda. Composition of vitamin c and/or vitamin a
FR2813789B1 (en) * 2000-09-11 2003-05-02 Ind E Com De Cosmeticos Natura NOVEL COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING AN ASSOCIATION OF VITAMIN C AND / OR WITH A FUCOSE COMPONENT AND USE OF SAID COSMETIC OR PHARMACY ASSOCIATION
JP2002308746A (en) * 2001-04-05 2002-10-23 Dongsung Pharm Co Ltd Composition for hairdye
EP1398019A1 (en) 2002-09-13 2004-03-17 Cognis France S.A. Method for protecting and modulating the dermal-epidermal junction
CN1988883B (en) * 2004-05-21 2010-06-02 株式会社故里村开发中心 Scalp and hair-care composition
KR100784486B1 (en) 2007-01-08 2007-12-11 주식회사 에스티씨나라 Cosmetic compositions for skin-tightening and method of skin-tightening using the same
JP6185372B2 (en) * 2013-11-21 2017-08-23 ポーラ化成工業株式会社 Topical skin preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394920A1 (en) * 1989-04-24 1990-10-31 Revlon Consumer Products Corporation Hair enrichment composition and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394920A1 (en) * 1989-04-24 1990-10-31 Revlon Consumer Products Corporation Hair enrichment composition and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Henkel Declares War on Premature Aging Induced by UV Radiation" DRUG AND COSMETIC INDUSTRY,1996, Seite 101 XP000852639 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068040A2 (en) * 2000-03-17 2001-09-20 L'oreal The use of plant extracts and sugars to protect keratinous tissue
WO2001068040A3 (en) * 2000-03-17 2002-05-16 Oreal The use of plant extracts and sugars to protect keratinous tissue
US6861077B1 (en) 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
WO2001089459A2 (en) * 2000-05-23 2001-11-29 L'oreal S.A. The use of plant extracts in a cosmetic composition to protect keratinous fibers
WO2001089459A3 (en) * 2000-05-23 2002-05-23 Oreal The use of plant extracts in a cosmetic composition to protect keratinous fibers
FR2824476A1 (en) * 2001-05-14 2002-11-15 Clarins Lab New composition comprising at least one colloidal glycoprotein complex and at least one Morera fluviatilis extract, for protecting the skin against the effects of low temperatures
US8691194B2 (en) 2002-12-12 2014-04-08 R.B.T (Rakuto Bio Technologies) Ltd. Methods of producing lignin peroxidase and its use in skin and hair lightening
US9693946B2 (en) 2002-12-12 2017-07-04 R.B.T. (Rakuto Bio Technologies) Ltd. Methods of producing lignin peroxidase and its use in skin and hair lightening
GB2402676B (en) * 2003-06-13 2007-11-21 Coletica Cosmetic use by topical application of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of skin elastic fibres
US8906425B2 (en) 2003-06-13 2014-12-09 Basf Beauty Care Solutions France S.A.S. Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers
DE202016003916U1 (en) 2015-06-29 2016-10-11 Hans Werner Bierganns emulsion

Also Published As

Publication number Publication date
EP1079795A2 (en) 2001-03-07
DE19823552A1 (en) 1999-12-02
CA2333544A1 (en) 1999-12-02
WO1999060989A3 (en) 2000-03-02
JP2002516263A (en) 2002-06-04
AU4262599A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
DE102015221460B4 (en) Permanent waving process with improved care performance and waving effect
EP1812117B1 (en) Method for restructuring keratin fibers
WO1994007458A1 (en) Hair after-treating agents
DE10005162A1 (en) Hair-treating compositions giving improved combability contain fatty acid, oil and zwitterionic) surfactant
EP1009367B1 (en) Use of a combination of active substances and agent for protecting keratinic fibers
DE102007013145A1 (en) Waving agents with hair fiber structure
WO2005115315A1 (en) Method and composition for restructuring keratin fibers
WO1999060989A2 (en) Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
WO2000061099A1 (en) Aqueous cosmetic product which contains tartaric or citric acid esters of the alkyl polyglucose and an acidic active substance with preservative properties
EP1404286B1 (en) Hair treatment agent with carnitine tartrate
DE19540853A1 (en) Hair treatment agents
EP0648103B1 (en) Hair conditioner
DE102006047733A1 (en) Use of dandelion extract to promote hair thickness and stimulate hair growth
EP0648104B1 (en) Hair-treatment agents
DE10243626A1 (en) Hair treatment composition containing an active ingredient combination with liposomes
EP1154752A1 (en) Preparations for treating keratin fibres
EP1302191B1 (en) Foamable composition for hair care
DE102004045253A1 (en) New cationic diagonally cross linked copolymer useful for improving physical characteristics of keratinic fibers (preferably human hair) and for styling and conditioning hairs
WO1997039724A1 (en) Solid agent for the treatment of keratinous fibres
WO2008031685A1 (en) Root extract of harpagophytum for stimulating hair growth
WO2008031684A1 (en) Apium graveleons extract for stimulating hair growth
DE102008063280A1 (en) Waving agent with aloe vera

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ HU JP KR MX NZ PL RU SI SK TR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ HU JP KR MX NZ PL RU SI SK TR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999953283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 508407

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2333544

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 42625/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999953283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09701196

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999953283

Country of ref document: EP